Latest Surfactants Stories
WARRINGTON, Pa., June 10, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that on June 7,( )2013 it submitted a response to the U.S. Food and Drug Administration's (FDA) recent correspondence relating to Discovery Labs' recently updated product specifications for SURFAXIN(®). Discovery Labs expects that the FDA may take up to four months to review...
DUBLIN, April 26, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/jlthkh/surfactants) has announced the addition of the "Surfactants Market By Product Types [Anionic, Non-Ionic, Cationic, Amphoteric], Substrates [Synthetic/Petrochemical, Bio-Based/ Natural/Green], Geography & Applications - Global Industry Trends And Forecasts To 2017" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )...
WARRINGTON, Pa., April 15, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the U.S. Food and Drug Administration (FDA) has requested clarification and provided recommendations regarding the recently-updated product specifications for SURFAXIN(®). Discovery Labs plans to provide a response to the FDA within two months. FDA procedure provides up...
WARRINGTON, Pa., March 29, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the release of two peer-reviewed publications related to SURFAXIN(®) (lucinactant) Intratracheal Suspension. SURFAXIN, currently the only FDA approved synthetic alternative to animal-derived surfactants in the U.S., was highlighted in the December issue of the Journal of...
WARRINGTON, Pa., March 6, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) will report fourth quarter 2012 results on Wednesday, March 13, 2013 before the open of the U.S. financial markets. The Company will also host a conference call at 10:00 a.m. ET that same day to discuss the fourth quarter financial results and other business updates. A question-and-answer session will follow management's remarks. To access the conference call and participate in the...
WARRINGTON, Pa., Feb. 13, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that it has entered into a secured loan facility with Deerfield Management Company, L.P. (Deerfield) for up to $30.0 million in financing. Deerfield is a leading healthcare investment firm with more than $3.5 billion of assets currently under management. "We are...
WARRINGTON, Pa., Dec. 4, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the release of data from a new pharmacoeconomic analysis demonstrating that the previously-reported reduced rate of reintubation in preterm infants treated with SURFAXIN(® )may also result in an average potential hospital cost savings of $389,247 per 100 treated infants by reducing the frequency of bronchopulmonary dysplasia (BPD) when compared with reintubation rates of...
DALLAS, November 26, 2012 /PRNewswire/ -- The report "Surfactants Market by Product Types [Anionic, Non-Ionic, Cationic, Amphoteric], Substrates [Synthetic/Petrochemical, Bio-Based/ Natural/Green], Geography & Applications - Global Industry Trends and Forecasts to 2017" defines and segments the surfactant market with analysis and forecasting of the global volume and revenue. The global surfactant consumption revenue is expected to grow from $27,040 million in 2012 to...
WARRINGTON, Pa., Sept. 27, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), today announced the initiation of four research projects designed to explore the use of its proprietary KL(4) surfactant technology for the prevention and treatment of acute lung injury (ALI). Discovery Labs believes that KL(4) surfactant may be an effective intervention for people at risk for, or with, ALI. The company is collaborating with leading research institutions in a series of...
